Eosinophilic asthma with chronic rhinosinusitis/nasal polyps and biologic agents

Creative Commons License

YILMAZ İ.

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, cilt.67, sa.4, ss.292-299, 2019 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 67 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5578/tt.68953
  • Dergi Adı: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.292-299
  • Anahtar Kelimeler: Severe asthma, eosinophilic asthma, chronic rhinosinusitis/nasal polyp, asthma phenotype, biologics, AIRWAY INFLAMMATION, NASAL POLYPS, PHENOTYPES, BENRALIZUMAB, EFFICACY, PHASE-3, IL-5, IDENTIFICATION, MEPOLIZUMAB, EXPRESSION
  • Erciyes Üniversitesi Adresli: Evet

Özet

The current understanding in severe asthma management is the targeted therapy approach with the evaluation of phenotypes and biomarkers. Therefore, personalized treatments are recently more prominent. Eosinophilic asthma with chronic rhinosinusitis/nasal polyps (CRSwNP) is one of the severe asthma phenotypes which needs a personalized treatment approach. Biological agents which specifically target type 2 (T2) high inflammation have been used in this severe asthma phenotype with a preferable safety profile. In the present review, biological agents in eosinophilic asthma with CRSwNP will be discussed.